Akio Tsutaho

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Ari Hashimoto · 4 shared papers, 2019–2022 · strength 0.48
   • Paper ARF6-AMAP1 pathway induces pancreatic cancer cells to express immunosuppressive chemokines DOI 10.21203/rs.3.rs-1897319/v1↗
   • Paper Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti… DOI 10.1186/s12964-021-00733-y↗
   • Paper High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic canc… DOI 10.1186/s12964-020-00608-8↗
2. Hisataka Sabe · 4 shared papers, 2019–2022 · strength 0.48
   • Paper ARF6-AMAP1 pathway induces pancreatic cancer cells to express immunosuppressive chemokines DOI 10.21203/rs.3.rs-1897319/v1↗
   • Paper Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti… DOI 10.1186/s12964-021-00733-y↗
   • Paper High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic canc… DOI 10.1186/s12964-020-00608-8↗
3. Satoshi Hirano · 4 shared papers, 2019–2022 · strength 0.48
   • Paper ARF6-AMAP1 pathway induces pancreatic cancer cells to express immunosuppressive chemokines DOI 10.21203/rs.3.rs-1897319/v1↗
   • Paper Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti… DOI 10.1186/s12964-021-00733-y↗
   • Paper High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic canc… DOI 10.1186/s12964-020-00608-8↗
4. Shigeru Hashimoto · 4 shared papers, 2019–2022 · strength 0.48
   • Paper ARF6-AMAP1 pathway induces pancreatic cancer cells to express immunosuppressive chemokines DOI 10.21203/rs.3.rs-1897319/v1↗
   • Paper Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti… DOI 10.1186/s12964-021-00733-y↗
   • Paper High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic canc… DOI 10.1186/s12964-020-00608-8↗
5. Yoshihiro Nishikawa · 2 shared papers, 2019–2022 · strength 0.22
   • Paper ARF6-AMAP1 pathway induces pancreatic cancer cells to express immunosuppressive chemokines DOI 10.21203/rs.3.rs-1897319/v1↗
   • Paper ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of … DOI 10.1073/pnas.1901765116↗
6. Yuzo Kodama · 2 shared papers, 2019–2022 · strength 0.22
   • Paper ARF6-AMAP1 pathway induces pancreatic cancer cells to express immunosuppressive chemokines DOI 10.21203/rs.3.rs-1897319/v1↗
   • Paper ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of … DOI 10.1073/pnas.1901765116↗
7. Toshiyuki Takahashi · 1 shared paper, 2023 · strength 0.15
   • Paper A rare case of pancreatic ductal adenocarcinoma with ossification mimicking a pancreatic stone impaction. DOI 10.4103/eus-d-22-00008↗
8. Ryo Sugiura · 1 shared paper, 2023 · strength 0.15
   • Paper A rare case of pancreatic ductal adenocarcinoma with ossification mimicking a pancreatic stone impaction. DOI 10.4103/eus-d-22-00008↗
9. Yusuke Mizukami · 1 shared paper, 2019 · strength 0.07
   • Paper ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of … DOI 10.1073/pnas.1901765116↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.